The PAWS Pet Company and IntelliCell BioSciences to Bring Regenerative Cell Therapy to Animals
August 30 2011 - 7:00AM
Marketwired
The PAWS Pet Company, Inc. (OTCQB: PAWS) (PINKSHEETS: PAWS) or "the
Company," the innovative pet services company, today announced it
has entered into an exclusive license agreement with IntelliCell
BioSciences, Inc., "IntelliCell" (PINKSHEETS: SVFC), a leader in
regenerative medicine and the manufacturing of stromal vascular
fraction (SVF) containing adipose derived adult stem cells. Per the
terms of the agreement, The PAWS Pet Company is to exclusively
market and sell IntelliCell's SVF solution in the veterinary
market.
According to Hoovers, the U.S. veterinary services industry has
annual revenues estimated at $25 billion.
"This is an important step in the development of the Company,"
said Dan Wiesel, Chairman and CEO of The PAWS Pet Company. "This
exclusive world-wide license extends our service offering beyond
the pet transportation marketplace, into the fast growing market
for regenerative medicine for animals. Through our trusted position
with both Pet Parents and Veterinarians, we will introduce a
technology that we believe will improve the wellbeing of pets."
Dr. Steven Victor, Chairman and CEO of IntelliCell, added, "We
are pleased to be working with The PAWS Pet Company in bringing our
leading SVF solution to the treatment of animals. The benefits of
SVF in providing stem cell counts and viability checks for each
specimen processed, as well as enhanced quality and quantity of the
stem cells produced, will now be available to pets."
Dr. Jeff Werber, Director of Veterinary Services with The PAWS
Pet Company, commented, "SVF is a proven treatment for a number of
conditions including osteoarthritis, tendon repair, ligament
injuries and other traumatic and degenerative diseases. The higher
cell count from a smaller tissue sample means that Pets have a
faster road to recovery with SVF compared to legacy enzyme-based
stem cell treatments."
About The PAWS Pet Company
The PAWS Pet Company, Inc. provides innovative pet services. Its
wholly owned subsidiary Pet Airways is the only airline
specifically designed for the safe and comfortable transportation
of pets. Pet Airways' Pawsengers™ travel in the specially equipped
main cabin of its planes -- where pets are continuously monitored
by an In-Flight Pet Attendant and the climate is controlled for
maximum pet comfort. With Pet Airways, pet parents can be assured
their pets will be treated with tender, loving care by pet
professionals throughout the journey. The airline launched flight
operations in 2009 and currently serves coast-to-coast destinations
across the United States, including Los Angeles, Phoenix, Denver,
Omaha, Chicago, Baltimore, New York, Atlanta and Ft. Lauderdale.
The company has also announced its upcoming expansion to Orlando,
Dallas, Austin, Houston and St. Louis.
For more information on The PAWS Pet Company go to www.thepawspetcompany.com
About IntelliCell Biosciences, Inc.
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using stromal
vascular fraction derived from adult adipose tissue. IntelliCell
intends to initially focus on setting up tissue processing centers
throughout the United States with managing partners. The centers
will receive and employ the IntelliCell™ process to the adipose
stromal vascular fraction harvested by physicians in their own
offices, and then return the IntelliCells™ to the physicians the
same day labeled "autologous homologous." IntelliCell has already
established processing centers in New York City, Philadelphia,
Dallas/Ft. Worth, and New Orleans, and has entered into a licensing
agreement for a center in Palm Beach. In the future, IntelliCell
intends to pursue expansion to secondary markets and beyond the
U.S. through a combination of company-owned and licensed clinical
facilities. For additional information, visit
http://www.intellicellbiosciences.com or call 212 249 3050.
Forward-Looking Statements
This press release includes statements that may constitute
"forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements other than
statements of historical facts, including, without limitation,
statements regarding introduction of new products, market
penetration and product efficacy and adoption, are forward-looking
statements. Terminology such as "introduce," "may," "will,"
"expects," "intends," "plans," "projects," "estimates,"
"anticipates," "illustrates", or "believes" or the negative
thereof, any variation thereon or similar terminology are intended
to identify forward-looking statements. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially and adversely from the results
proposed in such statements. Important factors that could cause
actual results to differ from our expectations include, but are not
limited to: the costs and availability of financing; our ability to
maintain adequate liquidity; our ability to execute our business
plan; our ability to control costs; our ability to attract and
retain customers; general economic conditions; competitive pricing
pressures; governmental regulation; and statements of assumption
underlying any of the foregoing, as well as other factors set forth
under the caption "Risk Factors" in the Form 8-K filed with the
Securities and Exchange Commission ("SEC") on March 8, 2011 and
other filings with the SEC. Readers are cautioned not to place
undue reliance on these forward-looking statements which speak only
as of the date of this press release. All forward-looking
statements are qualified in their entirety by the foregoing
cautionary statements. We assume no duty to update or revise our
forward-looking statements based on changes in our expectations or
events after the date hereof.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Company Contact: Investor Relations 408 248 6000 ext. 198
Email Contact Investor Contact: Laurel Moody Corporate
Profile 646 810 0608 Email Contact